Soy constituents: Modes of action in low-density lipoprotein management

Nutrition Reviews

Volumn 67, Issue 4, 2009, Pages 222-234

  Van Ee, Jan H ^a  

^a ARCHER DANIELS MIDLAND COMPANY   (United States)

Author keywords

Concerted interplay; LDL management; Soy constituents

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; CHOLESTEROL; FATTY ACID; GLYCININ; ISOFLAVONE; LIGNAN; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN; OLEIC ACID; PALMITIC ACID; PHOSPHATIDYLCHOLINE; PHYTOSTEROL; SOYBEAN OIL; SOYBEAN PROTEIN; SPHINGOLIPID; STANOL ESTER; STEARIC ACID; STEROL;

ATHEROSCLEROSIS; BILE SECRETION; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; FEEDING BEHAVIOR; FOOD COMPOSITION; GENETICS; HUMAN; LIFESTYLE; LIPID ABSORPTION; LIPID OXIDATION; NONHUMAN; PARTICLE SIZE; REVIEW; SOYBEAN; ANIMAL; CHEMISTRY; DRUG EFFECT;

ANIMALS; HUMANS; LIPOPROTEINS, LDL; SOY FOODS; SOYBEAN PROTEINS;

EID: 67649890639     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2009.00192.x     Document Type: Review

References (174)

1. Acuff RV, Thedford SS, Papas AM, Hidiroglou NN, Odom TA. Relative bioavailability of RRR- and all-rac-alpha-tocopheryl acetate in humans: studies using deuterated compounds. Am J Clin Nutr. 1994;60:397-402.
2. Traber MG, Elsner A, Brigelius-Flohe R. Synthetic as compared with natural vitamin E is preferentially excreted as alpha-CEHC in human urine; studies using deuterated alpha-tocopheryl acetates. FEBS Lett. 1998;437:145-148.
3. Lamarche B, Tchernof A, Moorjani S, et al. Small dense low density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.
4. Fernandez AJB. Biological properties of dietary micronutrients: anti-oxidant capacity and structure activity relationships. PhD Thesis, Heinrich Heine University of Dusseldorf, Germany; 2003.
5. Blatter-Garin MC, Kalix B, Morabia A, James RW. Small, dense lipoprotein particles and reduced paraoxonase-1 in patients with the metabolic syndrome. J Clin Endocrin Metab. 2005;90:2264-2269.
6. Hopkins GJ, Barter PJ. Transfers of esterified cholesterol and triglyceride between high density and very low density lipoproteins: in vitro studies of rabbits and humans. Metabolism. 1980;29:546-550.
7. Law M. Plant sterols and stanols margarines and health. Biomedical J. 2000;320:861-864.
8. Ostlund RE. Phytosterols in human nutrition. Ann Rev Nutr. 2002;22:533-549.
9. Neil HAW, Huxley RR. Efficacy and therapeutic potential of plant sterols. Atherosclerosis. 2002;3(Suppl):11-15.
10. Jones MH. The importance of phytosterols and phytostanols for heart health. Innov Food Techn. 2005;26:88-89.
11. Gonella M. Plant sterols and stanols: an additional therapy for cholesterol management. Nutr Bytes. 2003;9:article 2.
12. Lichtenstein AH. Plant sterols and blood lipid levels. Curr Opin Clin Nutr Metab Care. 2002;5:147-152.
13. Miettinen TA, Gylling H. Regulation of cholesterol metabolism by dietary plant sterols. Curr Opin Lipidol. 1999;10:9-14.
14. Sierksma A, Weststrate JA, Meijer GW. Spreads enriched with plant sterols, either esterified 4,4 dimethylsterols or free 4 desmethylsterols, and plasma total and LDL cholesterol concentrations. Br J Nutr. 1999;82:273-282.
15. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995;333:1308-1312.
16. Wester I. Dose responsiveness to plant stanol esters. Eur Heart J. 1999;1(Suppl):S104-S108.
17. Vanstone CA, Raeini-Sarjaz M, Parsons WE, Jones PJ. Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. Am J Clin Nutr. 2002;76:1272-1278.
18. Clifton P. Plant sterols and stanols - comparison and contrasts. Sterols versus stanols in cholesterol-lowering: is there a difference? Atherosclerosis. 2002;3(Suppl):5-9.
19. Gylling H, Miettinen TA. Cholesterol reduction by different plant stanol mixtures and with variable fat intake. Metabolism. 1999;48:575-580.
20. Thompson GR, Grundy SM. History and development of plant sterol and stanol esters for cholesterol-lowering purposes. Am J Cardiol. 2005;96:D3-D9.
21. Miettinen TA, Vuoristo M, Nissinen M, Jarvinen HJ, Gylling H. Serum, biliary, and fecal cholesterol and plant sterols in colectomized patients before and during consumption of stanol ester margarine. Am J Clin Nutr. 2000;71:1095-1102.
22. Sane AT, Sinnett D, Delvin E, et al. Localization and role of NPC1L1 in cholesterol absorption in human intestine. Lipid Res. 2006;47:2112-2120.
23. Bietrix F, Yan D, Nauze M, et al. Accelerated lipid absorption in mice over-expressing intestinal SR-BI. J Biol Chem. 2006; 281:7214-7219.
24. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem. 2005;280:12710-12720.
25. Duan LP, Wang HH, Wang DQ. Cholesterol absorption is mainly regulated by the jejunal and ileal ATP-binding cassette sterol efflux transporters Abcg5 and Abcg8 in mice. J Lipid Res. 2004;45:1312-1323.
26. Calpe-Berdiel L, Rotllan N, Palomer X, Ribas V, Blanco-Vaca F, Escola-Gil JC. Direct evidence in vivo of impaired macrophage-specific reverse cholesterol transport in ATP-binding cassette transporter A1-deficient mice. Biochim Biophys Acta. 2005;1738:6-9.
27. Mulligan JD, Flowers MT, Tebon A, et al. ABCA1 is essential for efficient basolateral cholesterol efflux during the absorption of dietary cholesterol in chickens. J Biol Chem. 2003;278:13356-13366.
28. Plat J, Mensink RP. Increased intestinal ABCA1 expression contributes to the decrease in cholesterol absorption after plant stanol consumption. FASEB J. 2002;16:1242-1247.
29. Sirtori CR, Lovati MR. Soy proteins and cardiovascular disease. Curr Atheroscler Rep. 2001;3:47-53.
30. Anderson JW, Johnstone BM, Cook-Newell ME. Metaanalysis of effects of soy protein intake on serum lipids in humans. N Engl J Med. 1995;333:276-282.
31. Carroll KK. Hypercholesterolemia and atherosclerosis: effects of dietary protein. Fed Proc. 1982;41:2792-2796.
32. Descovich GC, Ceredi C, Gaddi A, et al. Multicentre study of soybean protein diet for outpatient hypercholesterolaemic patients. Lancet. 1980;2:1709-1712.
33. Sacks FM, Lichtenstein A, van Horn L, Harris W, Kris-Etherton PM, Winston M. Soy protein, isoflavones, and cardiovascular health an American Heart Association science advisory for professionals from the nutrition committee. Circulation. 2006;113:1034-1044. (Pubitemid 43879479)
34. Lin Y, Meijer GW, Vermeer MA, Trautwein EA. Soy protein enhances the cholesterol-lowering effect of plant sterol esters in cholesterol-fed hamsters. J Nutr. 2004;134:143-148.
35. Sirtori CR. Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer climacteric symptoms and osteoporosis. Drug Safety. 2001;24:665-682.
36. Lovati MR, Manzoni C, Canavesi A, et al. Soybean protein diet increases low-density lipoprotein receptor activity in mononuclear cells from hypercholesterolemic patients. J Clin Invest. 1987;80:1498-1502.
37. Baum JA, Teng H, Erdman JWJ, et al. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr. 1998;68:545-551.
38. Manzoni C, Duranti M, Eberini I, et al. Subcellular localization of soybean 7S globulin in HepG2 cells and LDL receptor up-regulation by its alpha' constituent subunit. J Nutr. 2003;133:2149-2155.
39. Duranti M, Lovati MR, Dani V, et al. The alpha' subunit from soybean 7S globulin lowers plasma lipids and upregulates liver beta-VLDL receptors in rats fed a hypercholesterolemic diet. J Nutr. 2004;134:1334-1339.
40. Cho SJ, Juillerat MA, Lee CH. Cholesterol lowering mechanism of soybean protein hydrolysate. J Agric Food Chem. 2007;55:10599-10604.
41. Lovati MR, Manzoni C, Gianazza E, et al. Soy protein peptides regulate cholesterol homeostasis in Hep G2 cells. J Nutr. 2000;130:2543-2549.
42. Castiglioni S, Manzoni C, Duva A, et al. Soy proteins reduce progression of a focal lesion and lipoprotein oxidability in rabbits fed a cholesterol-rich diet. Atherosclerosis. 2003; 171:163-170.
43. Okuda M, Inoue N, Azumi H, et al. Expression of glutaredoxin in human coronary arteries: its potential role in antioxidant protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1483-1487.
44. Aoki H, Otaka Y, Igarashi K, Takenaka A. Soy protein reduces paraquat-induced oxidative stress in rats. J Nutr. 2002; 132:2258-2262.
45. Takenaka A, Annaka H, Kimura Y, Aoki H, Igarashi K. Reduction of paraquat-induced oxidative stress in rats by dietary soy peptide. Biosci Biotechnol Biochem. 2003;67:278-283.
46. Chen H, Muramoto K, Yamauchi F, Nokihara K. Anti-oxidant activity of designed peptides based on the anti-oxidative peptide isolated from digests of a soybean protein. J Agric Food Chem. 1996;44:2619-2623.
47. Chen H, Muramoto K, Yamauchi F, Fujimoto K, Nokihara K. Anti-oxidative properties of histidine-containing peptides designed from peptide fragments found in the digests of a soybean protein. J Agric Food Chem. 1998;46:49-53.
48. Scheiber MD, Liu JH, Subbiah MT, Rebar RW, Setchell KD. Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause. 2001;8:384-392.
49. Jenkins DJA, Kendall CWC, Jackson CJC, et al. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. Am J Clin Nutr. 2002;76:365-372.
50. Gianazza E, Eberini I, Arnoldi A, Wait R, Sirtori CR. A proteomic investigation of isolated soy proteins with variable effects in experimental and clinical studies. J Nutr. 2003;133:9-14.
51. Moriyama T, Kishimoto K, Nagai K, et al. Soybean betaconglycinin diet suppresses serum triglyceride levels in normal and genetically obese mice by induction of betaoxidation, downregulation of fatty acid synthase, and inhibition of triglyceride absorption. Biosci Biotechnol Biochem. 2004;68:352-359.
52. Potter S. Overview of proposed mechanisms for the hypocholesterolemic effect of soy. J Nutr. 1995;125(Suppl): S606-S611.
53. Desroches S, Mauger JF, Ausman LM, Lichtenstein AH, Lamarche B. Soy protein favorably affects LDL size independently of isoflavones in hypercholesterolemic men and women. J Nutr. 2004;134:574-579.
54. St-Pierre AC, Cantin B, Dagenais GR, et al. Low density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25:553-559. (Pubitemid 40315677)
55. Koba S, Hirano T, Ito Y, et al. Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis. 2006;189:206-214.
56. Berneis K, Ch J, Muser J, Felix B, Miserez AR. LDL size and subclasses are markers of clinically apparent and nonapparent atherosclerosis. Metabolism. 2005;54:227-234.
57. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low density lipoprotein particles. Expert Opin Biol Ther. 2007;7:53-72.
58. Arora A, Nair MG, Strasburg GM. Anti-oxidant activities of isoflavones and their biological metabolites in a liposomal system. Arch Biochem Biophys. 1998;356:133-141.
59. Guo Q, Rimbach G, Moini H, Weber S, Packer L. ESR and cell culture studies on free radical-scavenging and antioxidant activities of isoflavonoids. Toxicology. 2002;179:171-180.
60. Wilson T, March H, Banz WJ, et al. Anti-oxidant effects of phyto- and synthetic-estrogens on cupric ion-induced oxidation of human low-density lipoproteins in vitro. Life Sci. 2002;70:2287-2297.
61. Kapiotis S, Hermann M, Held I, Seelos C, Ehringer H, Gmeiner BM. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler Thromb Vasc Biol. 1997;17:2868-2874.
62. Tikkanen MJ, Wahala K, Ojala S, Vihma V, Adlercreutz H. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proc Natl Acad Sci USA. 1998;95:3106-3110.
63. Wiseman H, O'Reilly JD, Adlercreutz H, et al. Isoflavone phytoestrogens consumed in soy decrease F(2)-isoprostane concentrations and increase resistance of low density lipoprotein to oxidation in humans. Am J Clin Nutr. 2000;72: 395-400.
64. Engelman HM, Alekel DL, Hanson LN, Kanthasamy AG, Reddy MB. Blood lipid and oxidative stress response to soy isoflavones and phytic acid in postmenopausal women. Am J Clin Nutr. 2005;81:590-596.
65. McVeigh BL, Dillingham BL, Lampe JW, Duncan AM. Effect of soy protein varying in isoflavone content on serum lipids in healthy young men. Am J Clin Nutr. 2006;83:244-251.
66. Davis JN, Kucuk O, Djuric Z, Sarkar FH. Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med. 2001;30:1293-1302.
67. Djuric Z, Chen G, Doerge DR, Heilbrun LK, Kucuk O. Effect of soy isoflavone supplementation on markers of oxidative stress in men and women. Cancer Lett. 2001;172:1-6.
68. Ryan-Borchers TA, Park JS, Chew BP, McGuire MK, Fournier LR, Beerman KA. Soy isoflavones modulate immune function in healthy postmenopausal women. Am J Clin Nutr. 2006;83:1118-1125.
69. Kris-Etherton P, Daniels SR, Eckers RH, et al. AHA conference proceedings: summary of the scientific conference on dietary fatty acids and cardiovascular health. Circulation. 2001;103:1034-1039.
70. Institute ofMedicine, Food and Nutrition Board. Dietary fats: total fat and fatty acids. In: Dietary Reference Intakes for Energy, Carbohydrates, Fiber, Fat, Fatty Acids, Cholesterol, Proteins and Amino Acids. Washington DC: National Academy Press; 2005:483-484.
71. JointWHO/FAO Expert Consultation. Diet, Nutrition and the Prevention of Chronic Diseases. Geneva: WHO Technical Report Series 916. 2003; Chapter 5.4:82.
72. Bonanome A, Grundy SM. Effect of dietary stearic acid on plasma cholesterol and lipoprotein levels. N Engl J Med. 1988;318:1244-1248.
73. Morena JJ, Mitjavila MT. The degree of unsaturation of dietary fatty acids and the development of atherosclerosis [review]. J Nutr Biochem. 2003;14:182-195.
74. Kris-Etherton PM. AHA science advisory: monounsatrurated fatty acids and risk of cardio vascular disease. J Nutr. 1999;129:2280-2284.
75. Lichtenstein AH. Dietary fat, carbohydrate and protein: effect on plasma lipoprotein patterns. J Lipid Res. 2006; 47:1661-1667.
76. Lichtenstein AH, Ausman LM, Carrasco W, Jenner JL, Ordovas JM, Schaefer EJ. Hydrogenation impairs the hypolipidemic effect of corn oil in humans. Arterioscler Thromb Vasc Biol. 1993;13:154-161.
77. Woollett LA, Spady DK, Dietschy JM. Saturated and unsaturated fatty acids independently regulate low density lipoprotein receptor activity and production rate. J Lipid Res. 1992;33:77-88.
78. Rumsey SC, Galeano NF, Lipschitz B, Deckelbaum RJ. Oleate and other long chain fatty acids stimulate low density lipoprotein receptor activity by enhancing acyl coenzyme A: cholesterol acyl transferase activity and altering intracellular regulatory cholesterol pools in cultured cells. J Biol Chem. 1995;270:10008-10016.
79. Satoh N, Shimatsu A, Kotani K, et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care. 2007;30:144-146.
80. Moreno JA, Perez-Jimenez F, Marin C, et al. The effect of dietary fat on LDL size is influenced by apolipoprotein E genotype in healthy subjects. J Nutr. 2004;134:2517-2522.
81. Paravar T. The Mediterranean diet, a protective effect on coronary heart disease. Nutr Bytes. 2005;10:article 2.
82. Moreno JA, Lopez-Miranda J, Perez-Martinez P, et al. Monounsaturated fatty acid-rich diet reduces macrophage uptake of plasma oxidised low-density lipoprotein in healthy young men. Br J Nutr. 2008;29:1-7.
83. Frito M, Guxens M, Corella D, et al. Effect of a traditional Mediterranean diet on lipoprotein oxidation. Arch Intern Med. 2007;167:1195-1203.
84. Mensink RP, Katan MB. Effects of dietary trans fatty acids on high-density lipoprotein cholesterol levels in healthy subjects. N Engl J Med. 1990;323:439-445.
85. Zock PL, Mensink RP. Dietary trans-fatty acids and serum lipoproteins in humans. Curr Opin Lipidol. 1996;7:34-37.
86. Mauger JF, Lichtenstein AH, Ausman LM, et al. Effect of different forms of dietary hydrogenated fats on LDL particle size. Am J Clin Nutr. 2003;78:370-375.
87. Wilson TA, Meservey CM, Nicolosi RJ. Soy lecithin reduces plasma lipoprotein cholesterol and early atherogenesis in hypercholesterolemic monkeys and hamsters: beyond linoleate. Atherosclerosis. 1998;140:147-153.
88. Parrado Rubio J, Miramontes E, Romero EJ, Bautista Palomas JD. Oryzbran increases HDL-cholesterol more than soya lecithin. Innov Food Tech. 2004;20:2-3.
89. Childs MT, Bowlin JA, Oglivie JT, Hazzard WR, Albers JJ. The contrasting effects of a dietary soya lecithin product and corn oil on lipoprotein lipids in normolipidemic and familial hypercholesterolemic subjects. Atherosclerosis. 1981;38: 217-222.
90. Wojcicki J, Pawlik A, Sanochowiec L, Katdenska M, Myssliwiec Z. Clinical evaluation of lecithin as a lipidlowering agent. Phytother Res. 1995;9:597-599.
91. Brook JG, Linn S, Aviram M. Dietary soya lecithin decreases plasma triglyceride levels and inhibits collagen and ADPinduced platelet aggregation. Biochem Med Metab Biol. 1986;35:31-39.
92. Cobb M, Turkki P, Linscheer W, Raheja K. Lecithin supplementation in healthy volunteers. Nutr Metab. 1980;24:228-237.
93. Polichetti E, Diaconescu N, de la Porte PL, et al. Cholesterollowering effect of soyabean lecithin in normolipidaemic rats by stimulation of biliary lipid secretion. Br J Nutr. 1996;75:471-481.
94. Zhang S,Wang T, Beitz D. Soy Lecithin But Not Egg Lecithin Decreased the Plasma Cholesterol Concentration in Golden Syrian Hamsters. Iowa State University Animal Industry Report 2006. AS leaflet R2080.
95. Jimenez MA, Scarino ML, Vignolini F, Mengheri E. Evidence that polyunsaturated lecithin induces a reduction in plasma cholesterol level and favourable changes in lipoprotein composition in hypercholesterolemic rats. J Nutr. 1990; 120:659-667.
96. Esnault-Dupuy C, Chanussot F, Lafont H, Chabert C, Hauton J. The relationship between HDL-, LDL-, liposomes, free cholesterol, biliary cholesterol and bile salts in the rat. Biochemie. 1987;69:45-52.
97. Rivabene R, Cantafora A, Yan CC, Castellano F, Bruscalupi F, Bravo E. Effect of HDL infusion on biliary secretion in perfused rat liver. Bioscience Reports. 1992;12:425-432.
98. Tungland BC, Meyer D. Nondigestible oligo and polysaccharides (dietary fiber): their physiology and role in human health and food. CompRev Food Sci Food Saf. 2002;3:73-92.
99. Rodriguez R, Jimenez A, Fernandez-Bolanos J, Guillen R, Heredia A. Dietary fibre from vegetable products as source of functional ingredients. Trends Food Sci Tech. 2006;17:3-15.
100. Anderson JW, Jones AE, Riddell-Mason S. Ten different fibers have significantly different effects on serum and liver lipids in cholesterol-fed rats. J Nutr. 1994;124:78-83.
101. Anderson JW, Spencer DB, Hamilton CC, et al. Oat-bran cereal lowers serum total and LDL cholesterol in hypercholesterolemic men. Am J Clin Nutr. 1990;52:495-499.
102. Haripriya S, Tharani N. Fiber on hyperlipidemic postmenopausal women. In: Descheemaeker K, Debruyne I, eds. Soy & Health, Clinical Evidence-Dietetic Applications. Izegem, Belgium: Ignace Debruyne & Associates; 2005:192.
103. Nicolosi RJ, Bell SJ, Bistrian BR, Greenberg I, Forse AF, Blackburn GL. Plasma lipid changes after supplementation with β-glucan fiber from yeast. Am J Clin Nutr. 1999;70: 208-212.
104. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterollowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69:30-42.
105. Jenkins DJA, Kendall CWC, Vuskan E, et al. Soluble fibre intake at a dose approved by the US Food and Drug Administration for a claim of health benefits: Serum lipid risk factors for cardiovascular disease assessed in a randomized controlled crossover trial. Am J Clin Nutr. 2002;75:834-839.
106. Andon MB, Anderson JW. State of the art reviews: the oatmeal-cholesterol connection: 10 years later. Am J Lifestyle Med. 2008;2:51-57.
107. Eggum BO. The influence of dietary fibre on protein digestion and utilization. In: Schweizar TF, Edwards CA, eds. Dietary Fibre, A Component of Food. London UK: Springer; 1992:153-165.
108. Dunaif G, Schneeman BO. The effect of dietary fiber on human pancreatic enzyme activity in vitro. Am J Clin Nutr. 1981;34:1034-1035. (Pubitemid 11035909)
109. Tielker C. Soya the miracle of nature. Innov Food Techn. 2006;30:36-37.
110. Andersson M, Ellegard I, Andersson H. Oat bran stimulates bile acid synthesis within 8 h as measured by 7alphahydroxy-4-cholesten-3-one. Am J Clin Nutr. 2002; 76:1111-1116.
111. Duss R. Oat bran: proven and advanced nutrition for your heart. Innov Food Techn. 2005;19:122-126.
112. Ellegard I, Andersson H. Oat bran rapidly increases bile acid excretion and bile acid synthesis: An ileostomy study. Eur J Clin Nutr. 2007;61:938-945.
113. Lia A, Hallmans G, Sandberg AS, Sundberg B, Aman P, Andersson H. Oat beta-glucan increases bile acid excretion and a fiber-rich barley fraction increases cholesterol excretion in ileostomy subjects. Am J Clin Nutr. 1995;62:1245-1251.
114. Marlett JA, Hosig KB, Vollendorf NW, Shinnick FL, Haack VS, Story JA. Mechanism of serum cholesterol reduction by oat bran. Hepatology. 1994;20:1450-1457.
115. Davy BM, Davy KP, Ho RC, Beske SD, Davrath LR, Melby CL. High-fiber oat cereal compared with wheat cereal consumption favorably alters LDL-cholesterol subclass and particle numbers in middle-aged and older men. Am J Clin Nutr. 2002;76:351-358.
116. Shrestha S, Volek JS, Udani J, et al. A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals. J Nutr. 2006;136:2492-2497.
117. Theriault A, Chao JT, Wang Q, Gapor A, Adeli K. Tocotrienol: a review of its therapeutic potential. Clinical Biochem. 1999;32:309-319.
118. Cooney RW, Franke AA, Harwood PJ, Hatch-Pigott V, Custer LJ, Mordan LJ. Gamma-tocopherol detoxification of nitrogen dioxide: superiority to alpha-tocopherol. Proc Natl Acad Sci USA. 1993;90:1771-1775.
119. Hosomi A, Arita M, Sato Y, et al. Affinity for alphatocopherol transfer protein as a determinant of the biological activities of vitamin E analogs. FEBS Lett. 1997;409: 105-108.
120. Traber MG, Kayden HJ. Preferential incorporation of alphatocopherol vs. gamma-tocopherol in human lipoproteins. Am J Clin Nutr. 1989;48:517-526.
121. Traber MG. Vitamin E regulatory mechanisms. Annu Rev Nutr. 2007;27:347-362.
122. Cohn W, Gross P, Grun H, Loechleiter F, Muller DP, Zulauf M. Tocopherol transport and absorption. Proc Nutr Soc. 1992;51:179-188.
123. Ribaya-Mercado JD, Ordovas JM, Russell RM. Effect of betacarotene supplementation on the concentrations and distribution of carotenoids, vitamin E, vitamin A and cholesterol in plasma lipoprotein and non-lipoprotein fractions in healthy older women. J Am Coll Nutr. 1995;14:614-620.
124. Emmert DH, Kirchner JT. The role of vitamin E in the prevention of heart disease. Arch Fam Med. 1999;8:537-542.
125. Singh U, Devaraj S, Jialal I. Vitamin E, oxidative stress and inflammation. Annu Rev Nutr. 2005;25:151-174.
126. Ghaffari MA, Ghiasvand T. Inhibitory activity of vitamin E on the susceptibility of LDL to oxidation reaction. Toxicol Lett. 2007;172(Suppl):S194.
127. Fernandez AJB. Biological properties of dietary miconutrients: anti-oxidant capacity and structure activity relation ships. PhD Thesis, Heinrich Heine Universiy of Dusseldorf; 2003.
128. Rainwater DL, Mahaney MC, Vandeberg JL, Wang XL. Vitamin E dietary supplementation significantly affects multiple risk factors for cardiovascular disease in baboons. Am J Clin Nutr. 2007;86:597-603.
129. Merrill AH, Schmelz EM, Dillehay DL, et al. The enigmatic lipid class: biochemistry, physiology and pathophysiology. Toxicol Appl Pharmacol. 1997;142:208-225.
130. Vesper H, Schmelz EM, Nikolova-Karakashian MN, Dillehay DL, Lynch DV, Merrill AH. Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr. 1999;129:1239-1250.
131. Gutierrez E, Wang T. Effect of processing on sphingolipid content in soybean products. J Am Oil Chem Soc. 2004; 81:971-977.
132. Kobayashi T, Shimizugawa T, Osakabe T, et al. A long-term feeding of sphingolipids affected the levels of plasma cholesterol and hepatic triacylglycerol but not tissue phospholipids and sphingolipids. Nutr Res. 1997;17:111-114.
133. Nieuwenhuizen WF, Emeis JJ, Havekes LM. Use of sphingolipids for prevention and treatment of atherosclerosis. World Patent. WO 2004 064820/009436.
134. Duivenvoorden I, Voshol PJ, Rensen PCN, et al. Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3-Leiden mice. Am J Clin Nutr. 2006;84:312-321.
135. Nieuwenhuizen WF, Duivenvoorden I, Voshol PJ, et al. Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis. Eur J Lipid Sci Tech. 2007;109:994-997.
136. Nilsson A. Sphingolipids in the gut? Which are the important issues? Eur J Lipid Sci Technol. 2007;109:971-976.
137. Mazur WM, Duke JA, Wahala K, Rasku S, Adlercreutz H. Isoflavonoids and lignans in legumes: nutritional and health aspects in humans. Nutr Biochem. 1998;9:193-200.
138. Penalvo JL. Plant lignans in soy and in soy isoflavonesbased supplements. In: Descheemaeker K, Debruyne I, eds. Soy & Health, Clinical Evidence-Dietetic Applications. Izegem, Belgium: Ignace Debruyne & Associates; 2005:77-83.
139. Vanharanta M, Voutilainen S, Nurmi T, et al. Association between low serum enterolactone and increased plasma F2-isoprotanes, ameasure of lipid peroxidation. Atherosclerosis. 2002;160:465-469.
140. Kangas L, Saarinen N, Mutanen M, et al. Anti-oxidant and anti-tumor effects of hydroxyl-matairesinol (HM-3000, HMR), a lignan isolated from the knots of spruce. Eur J Cancer Prev. 2002;11(Suppl):S48-S57.
141. Kang MH, Naito M, Sakai K, Uchida K, Osawa T. Mode of action of sesame lignans in protecting low density lipoprotein against oxidative damage in vitro. Life Sci. 2002;66: 161-171.
142. Dhar P, Chattopadhyay K, Bhattacharyya D, Ghosh S. Antioxidative effect of sesame lignans in diabetes mellitus blood: an in vitro study. J Oleo Sci. 2005;54:39-43.
143. Prasad K. Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed. Athersclerosis. 2005;179:269-275. (Pubitemid 40364620)
144. Zhang W,Wang X, Liu Y, et al. Dietary flaxseed lignan extract lowers plasma cholesterol and glucose concentrations in hypercholestereolaemic subjects. Br J Nutr. 2008; 99:1301-1309.
145. Owen AJ, Roach PD, Abbey M. Regulation of low density lipoprotein receptor activity by estrogens and phytoestrogens in a Hep2 cell model. Ann Nutr Metab. 2004;48:269-275.
146. Takashi I, Kushiro M, Takahashi Y, Shinohara K, Fukuda N, Sirato-Yasumoto S. Sesamin, a sesame lignan as a potent serum lipid lowering food component. JARQ. 2003;37:151-158.
147. Qureshi AA, Pearce BC, Nor RM, Gapor A, Peterson DM, Elson CE. Dietary a-tocopherol attenuates the impact of g-tocotrienol on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in chickens. J Nutr. 1996;126: 389-394.
148. Qureshi AA, Peterson DM, Hasler-Rapacz JO, Rapacz J. Novel tocotrienols of rice bran suppress cholesterogenesis in hereditary hypercholesterolemic swine. J Nutr. 2001;131: 223-230.
149. Tan BJ. Appropriate spectrum vitamin E and new perspectives on desmethyl tocopherols and tocotrienols. J Am Nutr Ass. 2005;8:35-42.
150. Qureshi AA, Bradlow BA, Brace L, et al. Response of hypocholesterolemic subjects to administratiom of tocotrienols. Lipids. 1995;30:1171-1177.
151. Qureshi AA, Mo H, Pacher L, Peterson DM. Isolation and identification of novel tocotrienols from rice bran with hypocholesterolemic, antioxidant, and antitumor properties. J Agric Food Chem. 2000;48:3130-3140.
152. Yu SG, Thomas AM, Gapor A, Tan BJ, Qureshi N, Qureshi AA. Dose-response impact of various tocotrienols on serum lipid parameters in 5-week-old female chickens. Lipids. 2006;41:453-461.
153. Iqbal J, Minhajuddin M, Beg ZH. Suppression of 7,12- dimethylbenz[alpha] anthracene-induced carcinogenesis and hypercholesterolaemia in rats by tocotrienol-rich fractions isolated from rice bran oil. Eur J Cancer Prev. 2003;12:447-453.
154. Qureshi AA, Sami SA, Salser WA, Khan FA. Dose dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans. Atherosclerosis. 2002;161:199-207.
155. Baliarsingh S, Beg ZH, Ahmad J. The therapeutic impacts of tocotrienols in type 2 diabetic patients with hyperlipidemia. Atherosclerosis. 2005;182:367-374.
156. Rasool AH, Yuen KH, Yusoff K, Wong AR, Rahman AR. Dose dependent elevation of plasma tocotrienol levels and its effect on arterial compliance, plasma total anti-oxidant status and lipid profile in healthy humans supplemented with tocotrienol rich vitamin E. J Nutr Sci Vitaminol. 2006;52:473-478.
157. Wahlqvist ML, Krivokuca-Bogetic Z, Lo CS, Hage B, Smith R, Lukito W. Differential serum responses of tocopherols and tocotrienols during vitamin supplementation in hypercholesterolemic individuals without change in coronary risk factors. Nutr Res. 1992;12(Suppl):S181-S201.
158. Mensink RP, van Houwelingen AC, Kromhout D, Hornstra G. A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins or platelet function in men with mildly elevated serum lipid concentrations. Am J Clin Nutr. 1999;69:2134-2139.
159. Mustad VA, Smith CA, Ruey PP, Edens NK, DeMichelle SJ. Supplementation with 3 compositionally different tocotrienol supplements does not improve cardiovascular disease risk factors in men and women with hypercholesterolemia. Am J Clin Nutr. 2002;76:1237-1243.
160. Parker PA, Pearce BC, Clarck RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3- methylglutaryl-coenzyme A reductase. J Biol Chem. 1993; 268:11230-11238.
161. Correll CC, Edwards PA. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutarylcoenzyme A reductase. J Biol Chem. 1994;269:17390-17393.
162. Lansberg PJ, Tuzgol S, van de Ree MA, Defesche JC, Kastelein JJP. Prevalentie van familiaire hypercholesterolemie onder volwassenen in vier huisartsenpraktijken hoger dan werd aangenomen. Ned Tijdschr Geneesk. 2000;144: 1437-1440.
163. van Aalst-Cohen ES, Jansen ACM, Tanck MWT, et al. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J. 2006;27:2240-2246.
164. Kathiresan S, Melander O, Anevski D, et al. A genotype score derived from a combination of validated SNPs previously associated with cholesterol levels has been shown to be an independent risk factor for incident cardiovascular disease, a new study has shown. N Engl J Med. 2008;358: 1240-1249.
165. Lusis AJ, Pajukanta P. A treasure trove for lipoprotein biology. Nat Genet. 2008;40:129-130.
166. Høie LH, Morgenstern ECA, Gruenwald J, et al. A doubleblind placebo-controlled clinical trial compares the cholesterol lowering effects of two different soy protein preparations in hypercholesterolemic subjects. Eur J Nutr. 2005;44:65-71.
167. Jenkins DJA, Kendall CWC, Nguyen TH, et al. Effect of plant sterols in combination with other cholesterol-lowering foods. Metabolism. 2008;57:130-139.
168. Simons LA, Fulcher L, Howes L, et al. Additive effect of plant sterol-ester margarine and cerivastatin in lowering lowdensity lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol. 2002;90:737-740.
169. Goldberg AC, Ostlund RE, Bateman JH, Schimmoeller L, McPherson TB, Spilburg CA. Effect of plant stanol tablets on low density lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol. 2006;97:376-379.
170. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. J Clin Ther. 2007;29:1354-1367.
171. Moreyra AE, Wilson AC, Koraym AA. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med. 2005;165:1161-1166.
172. Petchetti L, Frishman WH, Petrillo R, Raju K. Nutriceuticals in cardiovascular disease: psyllium. Cardiol Rev. 2007;15:116-122.
173. Jenkins DJA, Kendall CWC, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs Lovastatin on serum lipids and C-reactive protein. JAMA. 2003; 290:502-510.
174. Rodes KS, Weintraub MS, Biesemeier CK, Rubenfire M. The lipid management nutrition outcomes project: perspectives from a national experience in protocol